Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

• jaimeuss_admin
• 17 בSeptember 2018
• Research
• 0 Comments

Continue Reading

DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.

• jaimeuss_admin
• 6 בSeptember 2018
• Research
• 0 Comments

Continue Reading

Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Cellect Biotechnology Ltd.: Exposure to the global stem cells industry

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Safe-T: Private Investment of NIS 22.5M supports positive momentum that is in line with company’s strategy. Target price raised to NIS 9.38

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Brainsway Ltd.: The Company continues to generate consistent growth based on the rental model; we assume operating balance in 2018; Capital raising reflects the confidence of institutional investors. Price target remains within the forecast range.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

Brainsway Ltd.: The company continues with its lease-based model; we expect an operational balance by 2018; Credit line granted will support rapid growth. Target price unchanged.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading

BioLineRx Ltd.: Continued execution of multiple clinical development programs for the Company’s lead project – BL-8040; Investment by a principal investor reflects confidence in the company’s strategy. Target Price unchanged.

• jaimeuss_admin
• 30 בAugust 2018
• Research
• 0 Comments

Continue Reading